Avatrombopag Maleate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Avatrombopag Maleate: Repurposing Evaluation — No TxGNN Predictions Available
One-Sentence Summary
Avatrombopag maleate is a thrombopoietin receptor agonist (TPO-RA) used to treat thrombocytopenia in adults. The TxGNN model returned no predicted new indications for this drug in the current Evidence Pack, and key data fields including mechanism of action and safety information were not successfully populated. This evaluation cannot be completed until the data pipeline gaps are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not retrieved in this Evidence Pack |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not assessable |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No predicted indications were returned by TxGNN for avatrombopag maleate in this Evidence Pack. Without a target indication, mechanistic bridging analysis cannot be performed.
Mechanism of action data was flagged as a data gap (severity: High) and was not populated despite a successful DrugBank query being logged. This prevents any assessment of whether the drug's pharmacology could plausibly extend to a new disease area.
From publicly available knowledge, avatrombopag maleate belongs to the TPO receptor agonist class and stimulates platelet production — but without TxGNN's candidate output, there is no repurposing hypothesis to evaluate at this stage.
Finland Market Information
Avatrombopag maleate is currently not marketed in Finland. No Fimea authorizations are on record (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack is critically incomplete — TxGNN returned no predicted indications, mechanism of action is missing, and safety data (warnings, contraindications, DDI) was not retrieved. There is no repurposing hypothesis to evaluate.
To proceed, the following is needed:
- Re-run TxGNN prediction pipeline for avatrombopag maleate and confirm candidate indications are written to
predicted_indications - Retrieve MOA from DrugBank — a successful query was logged (result_count: 1) but data was not propagated into the Evidence Pack; investigate the parsing step
- Parse package insert — TFDA package insert query also returned 1 result (result_count: 1) but warnings and contraindications remain empty; check PDF extraction logic
- Confirm original approved indication from Fimea / EMA regulatory filings to establish the repurposing baseline
- Once the above are resolved, re-generate the Evidence Pack (v5+) and resubmit for full evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.